SCHEDULE 13G: Adage Capital Management Discloses 6.56% Passive Stake in Protara Therapeutics

Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has disclosed a passive beneficial ownership of 6.56% in Protara Therapeutics, Inc.'s common stock.

Summary

• Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating beneficial ownership in Protara Therapeutics, Inc.
• The Reporting Persons collectively beneficially own 2,250,000 shares of Protara Therapeutics, Inc. Common Stock.
• This ownership represents 6.56% of the total outstanding Common Stock of Protara Therapeutics, Inc.
• The percentage is calculated based on 34,319,772 shares of Common Stock outstanding, as reported by the Company in its Prospectus and Form 8-K filed on December 11, 2024.
• The Reporting Persons hold shared voting power and shared dispositive power over all 2,250,000 shares.
• The filing is made under Rule 13d-1(b), indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a factual disclosure of beneficial ownership, not a performance report or strategic announcement. The filing indicates a significant stake by a reputable investor, which could be seen positively, but the document itself is purely informational.

Future Outlook

This document does not provide any forward-looking statements or guidance regarding Protara Therapeutics, Inc.'s future performance or strategic direction. It is solely a disclosure of beneficial ownership.

Industry Context

This filing indicates a significant passive investment by a notable institutional investor, Adage Capital Management, in Protara Therapeutics, a company operating in the biotechnology or pharmaceutical sector. Such disclosures can signal institutional confidence in the company's long-term prospects, although the filing itself does not provide specific reasons for the investment beyond it being in the ordinary course of business.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 6.56% stake may be viewed positively, potentially signaling confidence in the company's value or future prospects. It also provides transparency regarding the ownership structure.

Key Dates

Keywords

Protara Therapeutics, Adage Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, SEC Filing, Biotechnology, Pharmaceuticals